Research programme: p38 MAP kinase inhibitors - LEO Pharma

Drug Profile

Research programme: p38 MAP kinase inhibitors - LEO Pharma

Alternative Names: p38 MAP kinase inhibitors research programme - LEO Pharma

Latest Information Update: 08 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LEO Pharma
  • Class Benzophenones; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 08 Apr 2008 Discontinued - Preclinical for Inflammation in Denmark (unspecified route)
  • 07 Sep 2004 Data presented at the 18th International Symposium on Medicinal Chemistry (ISMC-2004) have been added to the pharmacokinetics and Inflammation pharmacodynamics section
  • 28 Jan 2004 Preclinical trials in Inflammation in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top